000			04168ntm a2200337 i 4500
999			_c12946 _d12946
001			12102116
005			20211025113041.0
008			150118s2019 ua a f bm 000 0 eng |
040			_aEG-EULC _cEG-EULC _erda
041	0		_aeng _bara
082	0	4	_a572 _bA.F.S _222
100	1		_aAhmed, Sara Faisal Abdel Aal, _933876 _eauthor
245	1	0	_aAssociation of CTRP and chemokine ligand-2 in Egyptian diabetic women with or without CAD / _cSara Faisal Abdel Aal Ahmed, (Biochemistry teaching assistant, Faculty of Pharmaceutical Sciences and Pharmaceutical Industries, Future University in Egypt, B. Ph. Sci., Assuit University); Supervisors Prof. Dr. Hala Osman El- Mesallamy, (Professor of Biochemistry, Head of Biochemistry Department, Faculty of Pharmacy, Ain Shams University.), Prof. Dr. Mohamed Hesham El-Hefnawy, (Professor of Pediatric Endocrinology, Dean of the National Institute of Diabetes and Endocrinology.), Ass. Prof. Dr. Marwa Ismail Shabayek, (Assistant Professor of Biochemistry, Faculty of Pharmaceutical Sciences and Pharmaceutical Industries, Future University in Egypt.)
246	1	5	_aارتباط معدلات CTRP وكيموكاين ليجند - 2 في السيدات المصريات المصابات بداء السكري في وجود أو عدم وجود أمراض الشريان التاجي
264		1	_c2019
300			_a133 pages, 4 pages : _billustrations (black and white) ; _c24 cm
336			_2rdacontent _atext
337			_2rdamedia _aunmediated
338			_2rdacarrier _avolume
500			_aSupervisors Prof. Dr. Hala Osman El- Mesallamy, (Professor of Biochemistry, Head of Biochemistry Department, Faculty of Pharmacy, Ain Shams University.), Prof. Dr. Mohamed Hesham El-Hefnawy, (Professor of Pediatric Endocrinology, Dean of the National Institute of Diabetes and Endocrinology.), Ass. Prof. Dr. Marwa Ismail Shabayek, (Assistant Professor of Biochemistry, Faculty of Pharmaceutical Sciences and Pharmaceutical Industries, Future University in Egypt.)
502			_aThesis (M.Sc.)-Ain Shams university, Faculty of pharmacy, Department of Biochemistry, 2019.
504			_aIncludes bibliographical references.
520	3		_aRenal allograft survival requires multiple immunosuppressive drugs. This strategy may lead to gastric complications that necessitate gastro-protective medications, notably, proton pump inhibitors (PPI). This study aimed to compare the influence of pantoprazole and esomeprazole on serum cyclosporine trough levels (C0) in renal transplant recipients (RTR). A prospective, parallel, open-label trial was conducted on 47 adult RTR receiving cyclosporine doses adjusted to attain trough concentrations of 100 to 150 μg/L, mycophenolate mofetil (MMF) 750 mg q12 hour and prednisolone at 5 mg daily at Nasser Institute, Cairo, Egypt from January to September 2016. Patients were randomized into the esomeprazole group (25) or pantoprazole group (22) receiving the same dose (40 mg once daily). The study outcomes included clinical signs of rejection and renal function decline, assessed by elevations in serum creatinine, caused by cyclosporine level variations in either of the two study groups. Renal function, C0 and CBC measurements were measured at baseline and monthly for 6 months. The mean C0 values were higher in the pantoprazole group than in the esomeprazole group in the sixth month only (P = .007). Serum creatinine level was lower in the sixth month than at baseline in the esomeprazole group (P = .004). There were no signs of rejection biochemical or clinical in any of the study groups. In conclusion, PPIs should be used with caution and doses should be titrated to reach the C0 targets in RTR, which is of more importance in pantoprazole than esomeprazole to avoid C0 level elevation or decline affecting the allograft function
546			_aText in English, abstracts in English and Arabic.
650		0	_aBiochemistry
650		0	_aDiabetes _xComplications
650		0	_aCoronary heart disease
856	4	0	_3DSpace electronic resource _uhttp://repository.fue.edu.eg/xmlui/handle/123456789/5783
942			_cTHESIS _2ddc